Salvage of infected tumor prostheses

Current Orthopaedic Practice

Volumn 20, Issue 6, 2009, Pages 598-604

  Allison, Daniel C ^a   Franklin, Corinna C ^a   Lu, Amy D ^a   Menendez, Lawrence R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Endoprosthesis; Infection; Limb salvage; Tumor

Indexed keywords

SILVER; VANCOMYCIN;

AMPUTATION; BACTERIAL GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; ENDOPROSTHESIS; FEMUR OSTEOTOMY; HUMAN; INFECTION RATE; INFECTION RISK; LIMB SALVAGE; MYELOMA; OSTEOSARCOMA; PERSISTENT INFECTION; PRIORITY JOURNAL; PROSTHESIS INFECTION; REOPERATION; REVIEW; RISK FACTOR; STAPHYLOCOCCUS INFECTION; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 74549114843     PISSN: 19407041     EISSN: 19417551     Source Type: Journal    
DOI: 10.1097/BCO.0b013e3181ae391a     Document Type: Review

References (37)

1. Rougraff BT, Simon MA, Kneisl JS, et al. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur: a long term oncologic, functional, and quality of life study. J Bone Joint Surg. 1994;76:649-656.
2. Hardes J, Gerbert C, Schwappach A, et al. Characteristics and • outcomes of infections associated with tumor endoprostheses. Arch Orthop Trauma Surg. 2006;126:289-296. In their study of 30 endoprosthesis infections, these authors found that their most important risk factor for failed limb salvage was poor soft tissue condition (P< 0.0001).
3. Jeys LM, Grimer RJ, Carter SR, et al. Periprosthetic infection in ••, patients treated for an orthopaedic oncological condition. J Bone Joint Surg. 2005;87:841-849. In the largest ever case series focusing on endoprosthetic infection, these authors found statistical risks for infection: radiation therapy, myeloma, revision procedures (bushing exchange, pediatric expansions, patellar resurfacing), tibial or pelvic location, and joint replacement procedures. Amputation and the highest success of curing infection (98%), and two-stage revision had a higher rate of cure than one-stage retention (72% vs. 6%).
4. Lee SH, Oh JH, Lee KS, et al. Infection after prosthetic reconstruction in limb salvage surgery. Int Orthop. 2002;26:179-184.
5. Mittermayer F, Krepler P, Dominkus M, et al. Long-term followup of uncemented tumor endoprostheses for the lower extremity. Clin Orthop. 2001;388:167-177.
6. Ham SJ, Schraffordt KH, Veth RP, et al. Limb salvage surgery for primary bone sarcoma of the lower extremities: long-term consequences of endoprosthetic reconstructions. Ann Surg Oncol. 1998;5:423-436.
7. Holzer G, Windhager R, Kotz R. One-stage revision surgery for infected mega prostheses. J Bone Joint Surg. 1998;79:31-35.
8. Malawer MM, Chou LB. Prosthetic survival and clinical results with use of large-segment replacements in the treatment of high grade bone sarcomas. J Bone Joint Surg. 1995;77:1154-1165.
9. Horowitz SM, Glasser DB, Lane JM, et al. Prosthetic and extremity survivorship after limb salvage for sarcoma. How long do the reconstructions last? Clin Orthop. 1993;293:280-286.
10. Grimer RJ, Belthur M, Chandrasekar C, et al. Two-stage revision for infected endoprostheses used in tumor surgery. Clin Orthop. 2002;395:193-203.
11. Wirganowicz PZ, Eckardt JJ, Dorey FJ, et al. Etiology and results of tumor endoprosthesis revision surgery in 64 patients. Clin Orthop. 1999;358:64-74.
12. Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg. 2007;89:780-785.
13. Babkin Y, Raveh D, Lifschitz M, et al. Incidence and risk factors for surgical infection after total knee replacement. Scand J Inf Dis. 2007;39:890-895.
14. Minnema B, Vearnecombe M, Augustin A, et al. Risk factors for surgical-site infection following total knee arthroplasty. Inf Control Hosp Epidemiol. 2004;25:477-480.
15. Windsor RE, Bono JV. Infected total knee replacements. J Am Acad Orth Surg. 1994;2:44-53.
16. Patzakis MJ, Abdollahi K, Sherman R, et al. Treatment of chronic osteomyelitis with muscle flaps. Orthop Clin North Am. 1993;24:505-509.
17. Hanssen AD, Trousdale RT, Osmon DR. Patient outcome with reinfection following reimplantation for the infected total knee arthroplasty. Clin Orthop. 1995;321:55-67.
18. Jeys LM, Grimer RJ, Carter SR, et al. Post operative infection and •• increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol. 2007;14:2887-2895. Authors compared the 10-year survival of their osteosarcoma endoprosthetic reconstructions that became infected within their first year after surgery with those that did not become infected. The infected group's 10-year survival was 84.5% and opposed to 62.3% in the noninfected group (P< 0.017). This finding may indicate a immunologic link that could advance chemotherapeutics.
19. Manoso MW, Boland PJ, Healey JH, et al. Limb salvage of • infected knee reconstructions for cancer with staged revision and free tissue transfer. Ann Plast Surg. 2006;56:532-535. This recent article demonstrated a 91% success rate in controlling infection in knee endoprosthesis patients with poor soft tissue coverage by performing a two-stage revision procedure with an associated free soft tissue transfer.
20. Donati D, Biscaglia R. The use of antibiotic-impregnated cement in infected reconstructions after resection for bone tumours. J Bone Joint Surg. 1998;80:1045-1050.
21. Donati D, D'Arenzo R, Ercolani C, et al. Infection in limb salvage surgery for bone tumors. Eur J Orthop Surg Traum. 1995;5:71-74.
22. Jeys LM, Lusocombe JS, Grimer RJ, et al. The risks and benefits of •• radiotherapy with massive endoprosthetic replacement. J Bone Joint Surg. 2007;89:1352-1355. Authors studied 63 patients treated with both endoprosthetic reconstruction and radiation therapy for a bone tumor and concluded definitively that radiation therapy was associated with increased rate of infection (P < 0.0001). The infected patients also had a statistically higher risk of subsequent amputation than their non-infected counterparts (P = 0.02).
23. Gosheger G, Gebert C, Ahrens H, et al. Endoprosthetic • reconstruction in 250 patients with sarcoma. Clin Orthop. 2006;4350:164-171. Authors studied 250 patients who underwent endoprosthetic reconstruction in the treatment of sarcoma and found their extraarticular resections had a 6.2 fold increased risk of infection compared to their intraarticular infections (P = 0.004).
24. Grimer RJ, Shewell PC, Carter SR. Endoprosthetic replacement of the proximal tibia. J Bone Joint Surg. 1999;81:488-494.
25. Jeys LM, Grimer RJ, Carter SR, et al. Risk of amputation following limb salvage surgery with endoprosthetic replacement, in a consecutive series of 1261 patients. Int Orthop. 2003;27:160-163.
26. Lascalles BD, Dernell WS, Correa MT, et al. Improved survival associated in postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol. 2005;12:1073-1083.
27. Thrall DE, Withrow SJ, Powers BE, et al. Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay. Int J Radiat Oncol Biol Phys. 1990;18:1351-1357.
28. Jeys LM, Kulkarni A, Grimer RJ, et al. Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the •• appendicular skeleton and pelvis. J Bone Joint Surg. 2008;90:1265-1271. Authors followed 776 patients each for a minimum of 10 years and found their overall 10-year implant survival to be 58%. They experienced peri-endoprosthetic infection in 11.3%, which were treated with even groups of amputation, one-stage revision, and two-stage revision procedures. They found statistically increased rate of infection cure in the two-stage group when compared to the one-stage group (85% vs. 73%) (P = 0.026).
29. Neut D, van Horn JR, van Kooten TG, et al. Detection of biomaterial-associated infections in orthopaedic joint implants. Clin Orthop. 2003;413:261-268.
30. Dunn RS, Raghavan S, Volz RG. Ciprofloxacin attachment to porous-coated titanium surfaces. J Appl Bio Mater. 1994;5:325-331.
31. Harris LG, Richards RG. Staphylococcus aureus adhesion to different treated titianium surfaces. J Mater Sci Mater Med. 2004;15:311-314.
32. Nablo BJ, Prichard HL, Butler RD, et al. Inhibition of implant-associated infections via nitric oxide release. Biomaterials. 2005;26:6984-6990.
33. Bahna P, Dvorak T, Hanna H, et al. Orthopaedic metal devices coated with a novel antiseptic dye for the prevention of bacterial infections. Int J Antimicrob Agents. 2007;29:593-596.
34. Antoci VJ, Adams CS, Parvizi J, et al. Covalently attached •• vancomycin provides a nanoscale antibacterial surface. Clin Orthop. 2007;461:81-87. After incubation with S. aureus, titanium with covalently bonded vancomycin showed in vitro to have significantly less bacterial colonization by both electron microscopy and fluorescent immunostaining. The effect was noted to last at least 11 months, did not promote antibiotic resistance and did not interfere with bone cell adhesion.
35. Antoci VJ, Adams CS, Parvizi J, et al. The inhibition of Staphylococcus epidermidis biofilm formation by vancomycin-modified titanium alloy and implications for the treatment of periprosthetic infection. Biomaterials. 2008;29:4684-4690.
36. Antoci VJ, Adams CS, Hickok NJ, et al. Vancomycin bound to Ti rods reduces periprosthetic infection: preliminary study. Clin Orthop. 2007;461:88-95.
37. Goesheger G, Hardes J, Ahrens H, et al. Silver-coated megaendoprostheses in a rabbit model-an analysis of the •• infection rate and toxicologic side effects. Biomaterials. 2004;25:5547-5556. A rabbit peri-endoprosthetic infection model was used to compare 15 cases of titanium with 15 cases of silver-coated endoprosthesis reconstructions. The silver group showed decreased rates of gross clinical infection (7% as opposed to 47%) and decreased C-reactive protein, neutrophil count, and temperature (P<0.05). Ten rabbits with silver coated endoprostheses were monitored for silver toxicity that showed elevated serum and organ silver levels with pathologic or toxic changes.